William D. Waddill, serving as a director at Protagonist Therapeutics, Inc. (NASDAQ:PTGX), completed the sale of 9,000 shares of the company's common stock on June 10, 2026. The transaction was executed at a weighted average price of $107.68 per share, with the price per share varying between $107.02 and $108.00. The aggregate value of the sale reached approximately $969,120. This divestment takes place as the stock is trading close to its 52-week high of $111.45. The current trading level follows a significant 98% return over the preceding year. Market analysis indicates that the stock may be priced above its calculated fair value, with the $7 billion market capitalization suggesting considerable investor optimism regarding the company's prospects.
On the same day as the sale, Mr. Waddill exercised stock options to acquire 9,000 shares of common stock. The acquisition involved 3,000 shares purchased at $11.80 per share and an additional 6,000 shares bought at $16.54 per share. The total cost for these acquisitions was approximately $134,640. All stock options that were exercised were fully vested. Both the option exercises and the subsequent sale of shares were carried out under a pre-arranged 10b5-1 trading plan. Mr. Waddill initially adopted this trading plan on February 27, 2026. Following the completion of these transactions, Mr. Waddill directly holds 7,825 shares of Protagonist Therapeutics common stock.
Protagonist Therapeutics has recently been the subject of multiple analyst reports. Wolfe Research initiated coverage with an outperform rating, pointing to a promising early-stage pipeline and establishing a price target of $135. BMO Capital reiterated an outperform rating, citing momentum from commercial launches and potential regulatory approvals, with a price target of $112. Citizens increased its price target to $137, emphasizing the validation of the company's peptide platform through the approval of Icotyde for psoriasis. Johnson & Johnson, a partner in this development, views this approval as a significant opportunity. Jefferies maintained a buy rating with a $121 price target, supported by Johnson & Johnson's optimistic outlook on Icotyde's sales potential. Truist Securities also raised its price target to $121, citing positive feedback from Johnson & Johnson regarding the rapid market uptake of Icotyde. These analyst actions reflect a strong consensus on the company's growth prospects.
The company held $620 million in cash and equivalents as of March 31, 2026. This financial position supports an expected operational runway through 2028. The stock closed at 109.79, representing a change of +4.02 or +3.80%. The after-hours trading price was recorded at 109.79. Market data for PTGX is available through various financial platforms, which analyze the stock against thousands of other companies using numerous financial metrics to assess fundamentals, momentum, and valuation.